Sparstolonin-B

Category	Human immunodeficiency Virus (HIV)
CAS	1259330-61-4
Description	Sparstolonin B acts as a selective TLR2 and TLR4 antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-HIV and anticancer activities.

Quotation Now

Product Information

Synonyms	sparstolonin B\|1259330-61-4\|4,14-dihydroxy-8,15-dioxatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2(7),3,5,9(17),10,13-heptaen-12-one\|SCHEMBL16158994\|Sparstolonin B, >=98% (HPLC)\|HY-116213\|CS-0064377
Molecular Weight	268.22
Molecular Formula	C15H8O5
Canonical SMILES	C1=CC2=C(C=C1O)C3=COC(=C4C3=C(O2)C=CC4=O)O
Purity	≥98% (HPLC)
Solubility	In vitro: 10 mM in DMSO
Appearance	Light yellow to yellow (Solid)
Storage	Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month
Complexity	622
Exact Mass	268.03717335
In Vitro	Sparstolonin B (1-20 µM; 2-4 days) inhibits cell growth and viability of neuroblastoma cells. Sparstolonin B inhibits TLR ligand-induced cytokine expression in mouse macrophages. Sparstolonin B inhibits MyD88 recruitment to TLR4 and TLR2. Sparstolonin B generates reactive oxygen species (ROS) in neuroblastoma cells. Sparstolonin B reduces expression of N-myc in neuroblastoma cells. Cell Viability Assay Cell Line: SH-SY5Y, IMR-32, NGP, SKNF-1 and SK-N-BE(2) cells Concentration: 1 µM, 5 µM, 10 µM or 20 µM Incubation Time: 2-4 days Result: Effectively and dose-dependently inhibits the viability of all neuroblastoma cell lines after 2 days (SH-SY5Y and IMR-32), 3 days (NGP cells) or 4 days (SKNF-1 and SK-N-BE(2) cells) treatment.
In Vivo	Sparstolonin B (100 μg/mouse; i.p.) suppresses LPS-provoked inflammation in mice. Animal Model: 5-6-week-old male C57Bl/6 mice (body weight 18-20 g) Dosage: 100 μg/mouse Administration: I.p. Result: Significantly lower TNFα and IL-1β expression levels in LPS-induced sepsis mouse model.
Target	Toll-like Receptor (TLR); HIV
XLogP3-AA	1.5